EyePoint (EYPT) EBITDA (2010 - 2026)
EyePoint (EYPT) posted EBITDA of -$87.2 million for Q1 2026, down 24.0% sequentially from -$70.3 million in Q4 2025, and down 78.61% YoY from -$407.7 million in Q1 2025.
EyePoint (EYPT) EBITDA (2010 - 2026) Analysis & Trends
EyePoint has reported EBITDA for 17 years, with the latest figure at -$87.2 million in Q1 2026.
- Quarterly EBITDA fell 78.61% year-over-year to -$87.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$281.8 million (down 74.64% YoY) and the FY2025 annual result came in at -$243.4 million, down 66.9% from the prior year.
- EBITDA slipped to -$87.2 million in Q1 2026 per EYPT's latest filing, from -$70.3 million in the prior quarter.
- Over five years, EBITDA peaked at -$14.4 million in Q3 2023 and troughed at -$87.2 million in Q1 2026.
- A 5-year average of -$38.3 million and a median of -$33.3 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA jumped 62.61% in 2023, then slumped 176.62% in 2024.
- Over 5 years, EBITDA stood at -$43.7 million in 2022, then surged by 62.61% to -$16.4 million in 2023, then tumbled by 176.62% to -$45.2 million in 2024, then sank by 55.5% to -$70.3 million in 2025, then declined by 24.0% to -$87.2 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$87.2 million, -$70.3 million, and -$62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -97.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -97.38 Mn |
| Mar 31, 2026 | -87.23 Mn |
| Dec 31, 2025 | -70.35 Mn |
| Sep 30, 2025 | -62.03 Mn |
| Jun 30, 2025 | -62.23 Mn |
| Mar 31, 2025 | -48.84 Mn |
| Dec 31, 2024 | -45.24 Mn |
| Sep 30, 2024 | -32.75 Mn |
| Jun 30, 2024 | -34.55 Mn |
| Mar 31, 2024 | -33.32 Mn |
| Dec 31, 2023 | -16.35 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -22.76 Mn |
| Mar 31, 2023 | -21.55 Mn |
| Dec 31, 2022 | -43.74 Mn |
| Sep 30, 2022 | -18.40 Mn |
| Jun 30, 2022 | -19.22 Mn |
| Mar 31, 2022 | -18.28 Mn |
| Dec 31, 2021 | -18.05 Mn |
| Sep 30, 2021 | -15.31 Mn |